Analyst: Biden's insulin message won't negatively impact Novo Nordisk
The debate about prescription drug prices in the US is far from new, says Sydbank Analyst Søren Løntoft Hansen, pointing out that past years’ discounts on insulins haven’t stopped Novo Nordisk from booking record-breaking results.
by marketwire, translated by daniel pedersen
On Tuesday, President of the United States Joe Biden announced in his State of the Union Address that he would lower the cost of prescription drugs in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biden wants to cut costs of prescription drugs in the US
For subscribers
Joe Biden hopes to end "outrageous" insulin prices
For subscribers
.jpg&w=384&q=75)
